Do analysts rate OMER or NLTX?

Omeros presently has a consensus target price of $34.00, indicating a potential upside of 68.90%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.71 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, OMER or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 15.73 Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is OMER or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts recommend MGTX or NLTX?

MeiraGTx currently has a consensus price target of $24.71, suggesting a potential upside of 123.66%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MeiraGTx 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate NLTX or REPL?

Replimune Group has a consensus price target of $12.00, indicating a potential downside of 4.76%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Replimune Group 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger earnings and valuation, NLTX or REPL?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is NLTX or REPL more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Replimune Group N/A -159.32% -90.84%

Do analysts recommend NLTX or AKTS?

Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 81.48%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91

Is NLTX or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Aktis Oncology N/A N/A N/A

Do analysts recommend NLTX or IMTX?

Immatics has a consensus price target of $20.60, suggesting a potential upside of 147.30%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immatics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Neoleukin Therapeutics (NLTX) Competitors

$30.93 -2.67 (-7.95%)

As of 09/23/2026

Compare

NLTX vs. OMER, MGTX, REPL, AKTS, and IMTX

Should you buy Neoleukin Therapeutics stock or one of its competitors? Neoleukin Therapeutics's main competitors and comparable companies include Omeros (OMER), MeiraGTx (MGTX), Replimune Group (REPL), Aktis Oncology (AKTS), and Immatics (IMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neoleukin Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Neoleukin Therapeutics' return on equity of -37.22% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	15.73
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

48.8% of Omeros shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Omeros had 12 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 12 mentions for Omeros and 0 mentions for Neoleukin Therapeutics. Omeros' average media sentiment score of 0.38 beat Neoleukin Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Overall Sentiment
Omeros	Neutral
Neoleukin Therapeutics	Neutral

Omeros has a beta of 2.6, meaning that its stock price is 160% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Omeros presently has a consensus target price of $34.00, indicating a potential upside of 68.90%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Omeros beats Neoleukin Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

MeiraGTx currently has a consensus price target of $24.71, suggesting a potential upside of 123.66%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, MeiraGTx had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for MeiraGTx and 0 mentions for Neoleukin Therapeutics. MeiraGTx's average media sentiment score of 0.40 beat Neoleukin Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Overall Sentiment
MeiraGTx	Neutral
Neoleukin Therapeutics	Neutral

MeiraGTx has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Neoleukin Therapeutics has lower revenue, but higher earnings than MeiraGTx. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	13.04	-$114.20M	$0.71	15.56
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

MeiraGTx has a net margin of 19.87% compared to Neoleukin Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MeiraGTx beats Neoleukin Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Replimune Group?

Neoleukin Therapeutics (NASDAQ:NLTX) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Neoleukin Therapeutics' return on equity of -37.22% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Replimune Group	N/A	-159.32%	-90.84%

Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Replimune Group has a consensus price target of $12.00, indicating a potential downside of 4.76%. Given Replimune Group's stronger consensus rating and higher probable upside, analysts clearly believe Replimune Group is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

In the previous week, Replimune Group had 10 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 10 mentions for Replimune Group and 0 mentions for Neoleukin Therapeutics. Replimune Group's average media sentiment score of 0.11 beat Neoleukin Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Replimune Group	Neutral

Summary

Replimune Group beats Neoleukin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Neoleukin Therapeutics (NASDAQ:NLTX) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neoleukin Therapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Aktis Oncology	$6.50M	162.33	-$63.73M	-$0.82	N/A

Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 81.48%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Aktis Oncology	N/A	N/A	N/A

In the previous week, Aktis Oncology had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 0 mentions for Neoleukin Therapeutics. Aktis Oncology's average media sentiment score of 0.92 beat Neoleukin Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Aktis Oncology	Positive

Summary

Aktis Oncology beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Immatics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Neoleukin Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Neoleukin Therapeutics' return on equity of -37.22% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Immatics	-495.71%	-47.41%	-39.45%

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neoleukin Therapeutics has higher earnings, but lower revenue than Immatics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Immatics	$54.60M	20.85	-$222.26M	-$1.86	N/A

Immatics has a consensus price target of $20.60, suggesting a potential upside of 147.30%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Immatics had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Immatics and 0 mentions for Neoleukin Therapeutics. Immatics' average media sentiment score of 0.77 beat Neoleukin Therapeutics' score of 0.00 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Immatics	Positive

Summary

Immatics beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$290.68M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-9.95	14.00	274.40	25.76
Price / Sales	N/A	1,342.46	688.47	106.32
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	2.79	15.46	10.52	6.34
Net Income	-$57.56M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-4.57%	-1.96%	-0.94%	-0.16%
1 Month Performance	-21.97%	-8.13%	-4.24%	-4.07%
1 Year Performance	79.30%	32.15%	16.39%	5.97%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$30.93 -7.9%	N/A	+83.6%	$290.68M	N/A	N/A	90	High Trading Volume
OMER Omeros	3.7994 of 5 stars	$17.34 +1.0%	$38.00 +119.1%	+379.3%	$1.24B	N/A	13.55	175	Analyst Upgrade Insider Trade
MGTX MeiraGTx	3.7711 of 5 stars	$12.76 flat	$26.17 +105.1%	+33.3%	$1.23B	$81.39M	17.97	393	News Coverage Analyst Upgrade Gap Down
REPL Replimune Group	1.3944 of 5 stars	$12.96 -0.5%	$12.00 -7.4%	+202.9%	$1.22B	N/A	N/A	465
AKTS Aktis Oncology	2.6944 of 5 stars	$22.71 +1.3%	$35.63 +56.9%	N/A	$1.20B	$6.50M	N/A	79	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. OMER, MGTX, REPL, AKTS, and IMTX

How does Neoleukin Therapeutics compare to Omeros?

Summary

How does Neoleukin Therapeutics compare to MeiraGTx?

Summary

How does Neoleukin Therapeutics compare to Replimune Group?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Summary

How does Neoleukin Therapeutics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. OMER, MGTX, REPL, AKTS, and IMTX

How does Neoleukin Therapeutics compare to Omeros?

Is OMER or NLTX more profitable?

Which has better earnings & valuation, OMER or NLTX?

Do insiders and institutionals believe in OMER or NLTX?

Does the media prefer OMER or NLTX?

Which has more risk & volatility, OMER or NLTX?

Do analysts rate OMER or NLTX?

Summary

How does Neoleukin Therapeutics compare to MeiraGTx?

Do analysts recommend MGTX or NLTX?

Does the media refer more to MGTX or NLTX?

Which has more volatility and risk, MGTX or NLTX?

Which has stronger earnings and valuation, MGTX or NLTX?

Is MGTX or NLTX more profitable?

Do institutionals and insiders have more ownership in MGTX or NLTX?

Summary

How does Neoleukin Therapeutics compare to Replimune Group?

Do institutionals and insiders have more ownership in NLTX or REPL?

Is NLTX or REPL more profitable?

Which has more volatility and risk, NLTX or REPL?

Do analysts rate NLTX or REPL?

Which has stronger earnings and valuation, NLTX or REPL?

Does the media favor NLTX or REPL?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Do insiders & institutionals hold more shares of NLTX or AKTS?

Which has stronger earnings & valuation, NLTX or AKTS?

Do analysts recommend NLTX or AKTS?

Is NLTX or AKTS more profitable?

Does the media prefer NLTX or AKTS?

Summary

How does Neoleukin Therapeutics compare to Immatics?

Is NLTX or IMTX more profitable?

Which has more volatility and risk, NLTX or IMTX?

Do insiders and institutionals hold more shares of NLTX or IMTX?

Which has better valuation & earnings, NLTX or IMTX?

Do analysts recommend NLTX or IMTX?

Does the media favor NLTX or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools